利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

83 条记录 (耗时 0.048 秒)

    Computer account management system and realizing method thereof
    53.
    发明授权
    Computer account management system and realizing method thereof 有权
    计算机帐户管理系统及其实现方法

    公开(公告)号：US09047462B2

    公开(公告)日：2015-06-02

    申请号：US14342121

    申请日：2012-04-18

    申请人： Zhiwei Xu ,  Guojie Li ,  Xiaolin Li ,  Yi Xie ,  Qiang Yue

    发明人： Zhiwei Xu ,  Guojie Li ,  Xiaolin Li ,  Yi Xie ,  Qiang Yue

    IPC分类号： G06F21/45 ,  H04L9/32 ,  H04L29/06

    CPC分类号： G06F21/45 ,  H04L9/3263 ,  H04L63/0815

    摘要： A computer account management system includes: an account management subsystem; an information asset management subsystem; an authentication (integrated) subsystem; a service (integrated) subsystem; and an account portal subsystem; wherein the account management subsystem manages information of physical accounts and logical account numbers; wherein the information asset management subsystem manages data information resources generated by network activities of physical account information; wherein the authentication subsystem provides an authentication integrated interface to the physical account numbers; wherein the service subsystem is a customizable interface which is open to internet or local network; wherein the account portal provides interfaces and tools of login, service list management of services subscribed or bought by the account, account information management and information asset management. The computer account management system is not bundled with services, seamlessly integrated with the user information asset and is lifetime-valid. The system can be used in account management of the internet.

    摘要翻译： 计算机帐户管理系统包括：帐户管理子系统; 信息资产管理子系统; 一个认证（集成）子系统; 一个服务（集成）子系统; 和帐户门户子系统; 其中所述帐户管理子系统管理物理账户和逻辑账号的信息; 其中信息资产管理子系统管理由物理账户信息的网络活动产生的数据信息资源; 其中所述认证子系统向所述实体帐号提供认证集成接口; 其中所述服务子系统是对互联网或本地网络开放的可定制接口; 其中帐户门户提供登录的接口和工具，帐户订阅或购买的服务的服务列表管理，帐户信息管理和信息资产管理。 计算机帐户管理系统不与服务捆绑，与用户信息资产无缝集成，具有终身有效性。 该系统可用于互联网的帐户管理。

    Supramolecular functionalization of graphitic nanoparticles for drug delivery
    57.
    发明授权
    Supramolecular functionalization of graphitic nanoparticles for drug delivery 有权
    石墨纳米粒子用于药物递送的超分子官能化

    公开(公告)号：US08535726B2

    公开(公告)日：2013-09-17

    申请号：US12178891

    申请日：2008-07-24

    申请人： Hongjie Dai ,  Zhuang Liu ,  Xiaolin Li ,  Xiaoming Sun

    发明人： Hongjie Dai ,  Zhuang Liu ,  Xiaolin Li ,  Xiaoming Sun

    IPC分类号： A61K9/16 ,  A61K9/50

    CPC分类号： A61K47/48215 ,  A61K9/0092 ,  A61K31/337 ,  A61K31/704 ,  A61K38/16 ,  A61K39/395 ,  A61K47/62 ,  A61K47/68 ,  A61K47/6925 ,  A61K47/6929 ,  A61K47/6949 ,  B82Y5/00 ,  Y10T428/2982

    摘要： Disclosed are nanoparticles, such as carbon nanotubes or other graphitic sheet materials having extended aromatic surfaces, which are used to deliver active agents such as drugs, labels or dyes (termed for convenience a “drug”) to the interior of cells. The nanoparticles are functionalized by a hydrophilic polymer or adsorption of an amphiphilic molecule to render them stable in suspension. The drug is therefore capable of release in the cell exterior. The drug is more rapidly released at lower pH, as found e.g., in tumor cells. The drug may also be linked to a branched chain hydrophilic polymer, so that each polymer molecule carries more than one drug bound by a cleavable linker.

    摘要翻译： 公开了纳米颗粒，例如碳纳米管或具有延伸芳族表面的其它石墨片材料，其用于将活性剂如药物，标记或染料（为方便起见称为“药物”）递送至细胞内部。 纳米颗粒通过亲水性聚合物或两亲性分子的吸附官能化，使其在悬浮液中稳定。 因此，该药物能够在细胞外释放。 药物在较低的pH下更快速释放，例如在肿瘤细胞中发现。 药物也可以连接到支链亲水性聚合物，使得每个聚合物分子携带多于一种可切割接头结合的药物。

    5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
    59.
    发明授权
    5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors 有权
    5-（4-（卤代烷氧基）苯基）嘧啶-2-胺化合物和组合物作为激酶抑制剂

    公开(公告)号：US08293757B2

    公开(公告)日：2012-10-23

    申请号：US12674416

    申请日：2008-08-19

    申请人： Valentina Molteni ,  Xiaolin Li ,  Xiaodong Liu ,  Donatella Chianelli ,  Juliet Nabakka ,  Jon Loren ,  Shuli You

    发明人： Valentina Molteni ,  Xiaolin Li ,  Xiaodong Liu ,  Donatella Chianelli ,  Juliet Nabakka ,  Jon Loren ,  Shuli You

    IPC分类号： A61K31/506 ,  C07D403/10 ,  C07D239/42

    CPC分类号： C07D239/42 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12

    摘要： The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3. Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-rapor b-raf kinases.

    摘要翻译： 本发明提供了可用作蛋白激酶抑制剂的式（1）化合物及其药物组合物，以及使用这些化合物治疗，改善或预防与异常或失调激酶活性相关的病症的方法。 在一些实施方案中，本发明提供了使用这些化合物治疗，改善或预防涉及c-kit，PDGFRα，PDGFR和bgr，CSF1R，AbI，BCR-AbI，CSK，JNK1，JNK2，p38异常活化的疾病或病症的方法 ，p70S6K，TGF＆bgr; SRC，EGFR，trkB，FGFR3。 Fes，Lck，Syk，RAF，MKK4，MKK6，SAPK2＆bgr; BRK，Fms，KDR，c-rapor b-raf激酶。

    Pyrimidine derivatives and compositions as C-kit and PDGFR kinase inhibitors
    60.
    发明授权
    Pyrimidine derivatives and compositions as C-kit and PDGFR kinase inhibitors 失效
    嘧啶衍生物和组合物作为C-kit和PDGFR激酶抑制剂

    公开(公告)号：US08268850B2

    公开(公告)日：2012-09-18

    申请号：US12598919

    申请日：2008-05-01

    申请人： Xiaolin Li ,  Xiaodong Liu ,  Valentina Molteni

    发明人： Xiaolin Li ,  Xiaodong Liu ,  Valentina Molteni

    IPC分类号： C07D401/14 ,  A61K31/444

    CPC分类号： C07D401/14 ,  C07D405/14

    摘要： The invention provides a novel class of pyrimidine derivatives, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.

    摘要翻译： 本发明提供了一类新颖的嘧啶衍生物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及c-kit，PDGFRα异常活化的疾病或病症 和PDGFR＆bgr; 激酶。